Cargando…
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
Venetoclax has been approved by the United States Food and Drug Administration since 2016 as a monotherapy for treating patients with relapsed/refractory chronic lymphocytic leukemia having 17p deletion. It has led to a breakthrough in the treatment of hematologic malignancies in recent years. Howev...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597043/ https://www.ncbi.nlm.nih.gov/pubmed/33292251 http://dx.doi.org/10.1186/s12935-020-01614-z |